Retatrutide (CAS 2381089-83-2)/retatrutide peptide

Retatrutide (CAS 2381089-83-2) is a high-purity pharmaceutical API classified as a novel triple receptor agonist, featuring a synthetic peptide molecular structure engineered to target GLP-1, GIP, and GCGR receptors simultaneously. Unlike dual agonists, it exerts synergistic effects: suppressing appetite, slowing gastric emptying, and enhancing insulin sensitivity—delivering superior weight reduction and glycemic control. This API exhibits prolonged duration of action (once-weekly administration) and excellent tolerability, addressing unmet needs in metabolic disorder management.

It caters to the core needs of metabolic drug manufacturers, anti-obesity formulation developers, and diabetes therapy suppliers. Widely applied in developing treatments for type 2 diabetes mellitus (T2DM) and obesity, it aligns with demand for innovative, multi-mechanism metabolic therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and peptide integrity testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing cutting-edge metabolic solutions, this Retatrutide API serves as a critical raw material for advancing weight loss and diabetes medication development.